Results 171 to 180 of about 6,085 (188)

Abstract 5452: Neuroendocrine negative RB1 WT SCLC and LCNEC

Cancer Research, 2020
Abstract Background: Based on genomics data generated in last few years about 15% of tumors diagnosed as large cell neuroendocrine carcinomas (LCNEC) are actually neuroendocrine negative. Interestingly, approximately similar percentage of small cell lung cancers (SCLC) are also neuroendocrine negative, historically known as SCLC variant ...
Dmitriy Sonkin, Anish Thomas, Beverly A. Teicher   +2 more
openaire   +1 more source

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

Lung Cancer, 2020
Little is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS.Thirty-seven consecutive patients with advanced LCNEC were selected from the Davidoff Cancer Center database. These were divided into groups A1 (patients treated with ICPi, n-23) and A2 (patients not treated with ICPi,
Alona Zer, Elizabeth Dudnik, Assaf Moore
exaly   +3 more sources

Large-Cell (Undifferentiated) Carcinoma (LCC) Versus Large-Cell Neuroendocrine Carcinoma (LCNEC)

2022
Faqian Li
exaly   +2 more sources

YAP1 status defines two intrinsic subtypes of LCNEC with distinct molecular features and therapeutic vulnerabilities

Clinical Cancer Research
Abstract Purpose: Large cell neuroendocrine carcinoma (LCNEC) is a high-grade neuroendocrine malignancy that, like small cell lung cancer (SCLC), is associated with the absence of druggable oncogenic drivers and dismal prognosis.
Yuanxin Xi, Alejandra Griselda Serrano, Neda Kalhor   +2 more
exaly   +3 more sources

Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review

Clinical Lung Cancer
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is an uncommon and aggressive malignancy, accounting for approximately 3% of all primary lung malignancies. Due to its rarity, the treatment paradigm for LCNEC is primarily derived from retrospective data from non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Anson Man Lok Yeung, James Chung Hang Chow   +1 more
openaire   +2 more sources

A case of ACTH secreting large cell neuroendocrine carcinoma (LCNEC) of bronchus

Oncology, Gastroenterology and Hepatology Reports, 2012
Bronchopulmonary neuroendocrine tumors account for only 20% of all lung carcinomas. These tumors are separated into four subtypes of low-grade (typical carcinoids), intermediate-grade (atypical carcinoids) and high-grade carcinomas which include large cell neuroendocrine carcinoma (LCNEC) and small-cell lung carcinoma (SCLC).
Appalanaidu Sasapu, David Smith, Theepha Thayalakulasingam, Arthur Zieske, Brian Boulmay, Fred Lopez   +5 more
openaire   +1 more source

Genetic subtypes of large cell neuroendocrine carcinoma (LCNEC) to predict response to chemotherapy.

Journal of Clinical Oncology, 2017
9061 Background: To treat LCNEC with non-small cell lung carcinoma type chemotherapy (NSCLC-ct, i.e. gemcitabine/taxanes or pemetrexed) or small cell lung carcinoma type (SCLC-ct, i.e. platinum-etoposide) is subject of debate. Molecular studies have identified two mutually exclusive subtypes in LCNEC, the co-mutated TP53 and RB1and the STK11/ KEAP1 ...
Jules Derks, Noémie Leblay, Robert Jan van Suylen, Erik Thunnissen, Michael den Bakker, Harry J.M. Groen, Egbert F. Smit, Ronald Damhuis, Esther van de Broek, Amélie Chabrier, Matthieu Foll, James McKay, Lynnette Fernandez-Cuesta, Ernst-Jan M. Speel, Anne-Marie C. Dingemans   +14 more
openaire   +1 more source

Characterization of genomic alterations in Chinese LCNEC and SCLC via comprehensive genomic profiling.

Journal of Clinical Oncology, 2019
1575 Background: LCNEC and SCLC are aggressive neuroendocrine carcinomas with overlap in clinical, histopathologic, morphologic and genomic features. Differential molecular features between the two subtypes have not been well elucidated, contributing the uncertainty for optimal clinical strategy for each subtype.
Lin Wu, Liming Cao, Likun Chen, Bo Zhu, Xiaohua HU, Lin Gen, Yingcheng Lin, Sheng Zhang, Cheng Huang, Wenying Peng, Meilin Jiang, Xinru Mao, Tengfei Zhang, Junyi Ye, Lu Zhang   +14 more
openaire   +1 more source

Large Cell Neuroendocrine Carcinoma (LCNEC) and Lymphoma

2020
Jing Feng, Qiang Li, Hongwu Wang, Faguang Jin, Hongmei Zhou   +4 more
openaire   +1 more source

Prognostic significance of YAP1 expression and its association with neuroendocrine markers in resected pulmonary large cell neuroendocrine carcinoma (LCNEC)

Translational Oncology, 2022
Jianming Ying, Junling Li, Xujie Sun
exaly